Skip to content

Shares (Basic) at other companies

Gilead Sciences logo
Gilead SciencesGILD
1.2B-0.3%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
68.2M+1.1%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
24.7M+1.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
418.5M+29.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
66.4M+52.1%
Vor Biopharma logo
Vor BiopharmaVOR
43M+589%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s shares (basic)?
Kyverna Therapeutics, Inc. (KYTX) reported shares (basic) of 60.4M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s shares (basic) changed year-over-year?
Kyverna Therapeutics, Inc.'s shares (basic) increased by 39.8% year-over-year, from 43.2M to 60.4M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s shares (basic)?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s shares (basic) has grown at a 676.6% compound annual growth rate (CAGR), from 2.9M to 174.1M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.